Patents
Patent Number: 5670146
This patent covers the various formulations of human p-CSF. It also covers the factor's use for stimulation of hematopoiesis. I wonder what the modern name for p-CSF is?
Inventors: Welte, Karl (New York, NY); Platzer, Erich (Erlangen, DE); Gabrilove, Janice L. (New York, NY); Mertelsm, Roland (Chappaqua, NY); Moore, Malcolm A. S. (Larchmont, NY)
Assignee: Sloan-Kettering Institute (New York, NY)
Date of First Priority Issue: Thursday March 28th, 1985
Patent Number: 5668104
This patent covers a protein that expands hematopoietic stem cells called FDF-3.
Inventors: Nakahata, Tatsutoshi (Matsumoto, JP); Kawano, Genji (Kamakura, JP); Sudo, Tetsuo (Kamakura, JP); Kojima, Katsuaki (Yokohama, JP)
Assignee: Toray Industries, Inc. (Tokyo, JP)
Date of First Priority Issue: Tuesday March 31st, 1992
Patent Number: 5665557
This patent covers the use of CDw109 for purification and identification of hematopoietic stem cells.
Inventors: Murray, Lesley (San Jose, CA); Sutherland, D. Robert (Oakville, CA)
Assignee: Systemix, Inc. (Palo Alto, CA); The Toronto Hospital Research Institute (Toronto, CA)
Date of First Priority Issue: Monday November 14th, 1994
Patent Number: 5662895
This patent covers the hematopoietic uses of a tumor derived hematopoiesis stimulator called pluripotent colony stimulating factor...what is the modern name of this???
Inventors: Welte, Karl (New York, NY); Platzer, Erich (Spardorf, DE); Gabrilove, Janice L. (New York, NY); Mertelsmann, Roland (Mainz, DE); Moore, Malcolm A. S. (Larchmont, NY)
Assignee: Sloan-Kettering Institute (New York, NY)
Date of First Priority Issue: Thursday March 28th, 1985
Patent Number: 5658761
This patent covers immortalized stromal cells, which can be used for gene therapy. These stromal cells appear to be similar to mesenchymal stem cells in some ways.
Inventors: Thalmeier, Karin (Munchen, DE); Dormer, Peter (Gilching, DE)
Assignee: Gsf-Forschungszentrum fur Umwelt und Gesundheit GmbH (OberscheleiBheim, DE)
Date of First Priority Issue: Wednesday July 7th, 1993
Patent Number: 5654189
This patent covers differentiated teratocarinoma cells as a source of neurons. The concepts and subject matter of this patent actually was used in clinical trials for stroke.
Inventors: Lee, Virginia (Philadelphia, PA); Pleasure, Samuel (Philadelphia, PA)
Assignee: Trustees of the University of Pennsylvania (Philadelphia, PA)
Date of First Priority Issue: Friday July 10th, 1992
Patent Number: 5654186
This patent covers a special population of stem cells that circulate in peripheral blood. Although the patent uses the word "mesenchymal" to describe the cells, these may not be true mesenchymal cells since they possess hematopoietic markers such as CD34 and CD45.
Inventors: Cerami, Anthony (Shelter Island, NY); Bucala, Richard J. (New York, NY)
Assignee: The Picower Institute for Medical Research (Manhasset, NY)
Date of First Priority Issue: Friday February 26th, 1993
Patent Number: 5654183
LNGFR expressing neural stem cells are patented. The use of these cells for targets of gene transfection, and subsequent administration of the transfected stem cells for therapeutic benefit is disclosed.
Inventors: Anderson, David J. (Altadena, CA); Stemple, Derek L. (Newton, MA)
Assignee: California Institute of Technology (Pasadena, CA)
Date of First Priority Issue: Thursday July 2nd, 1992
Patent Number: 5650299
This patent covers a cell line that produces a factor associated with inducing proliferation of stem cells. If this factor is not already commercialized, which it appears it is not, this patent is a great tool for starting a biotech company.
Inventors: Lawman, Michael J. P. (Orlando, FL); Lawman, Patricia D. (Orlando, FL); Denslow, Nancy D. (Gainesville, FL)
Assignee: The University of Florida (Gainesville, FL)
Date of First Priority Issue: Wednesday October 6th, 1993
Patent Number: 5648248
This patent teaches how to use hematopoietic stem cells as a stem cell source for the generation of dendritic cells. Since the dendritic cell is the most potent stimulator of the immune system, this patent is useful for generating a biological adjuvant for vaccines. The patent teaches that activation of the rel gene through a unique construct can be used for generation of dendritic cells out...
Inventors: Zenke, Martin (Schonow, DE); Boehmelt, Guido (North York, CA); Madruga, Jaime (Berlin, DE); Enrietto, Paula (Stony Brook, NY)
Assignee: Boehringer Ingelheim International GmbH (DE)
Date of First Priority Issue: Friday December 30th, 1994